This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Merrimack Initiates Phase 2 Clinical Study Of MM-111 In Advanced Gastroesophageal Cancers

CAMBRIDGE, Mass., July 22, 2013 (GLOBE NEWSWIRE) -- Merrimack Pharmaceuticals, Inc. (Nasdaq:MACK) today announced the enrollment of its first patient in a Phase 2 clinical trial of its bispecific antibody, MM-111, for the treatment of advanced gastric, esophageal and gastroesophageal junction (GEJ) cancers.

Overexpression of the HER2 (ErbB2) cell surface receptor has been reported in 7-34 percent of stomach and esophageal cancers. The HER2 receptor triggers tumor growth and survival when it binds together with an additional receptor known as HER3 (ErbB3) and another protein called heregulin. HER3 expression has been associated with poor prognosis in gastric cancer. MM-111 is designed to anchor to both receptors, HER2 and HER3, on the cell surface and block heregulin's ability to transmit tumor growth signals, thus inhibiting the tumor cell's ability to thrive.

This Phase 2 study is unique in that it is testing MM-111 in two different subsets of patients overexpressing the HER2 receptor:

  • The first set of patients traditionally receive trastuzumab-based therapy due to their HER2 score of 2+ or 3+ on the HercepTest® and/or have a positive fluorescence in situ hybridization status (FISH+). These patients will be randomized to receive either MM-111 combined with paclitaxel and trastuzumab or paclitaxel and trastuzumab.
  • The second set of patients in the study are usually not treated with HER2-targeted therapy because they have a HER2 2+ HercepTest® score and have a negative FISH status (FISH-) for the HER2 gene. Some of these patients may still have relatively high HER2 levels but there are currently no HER2-targeted therapy options available for them. These patients will be randomized to receive either MM-111 combined with paclitaxel or paclitaxel alone.

"This Phase 2 study in advanced gastric, esophageal and GEJ cancers addresses two distinct HER2-expressing patient populations with unmet needs who are often limited in their chemotherapeutic and targeted therapy options. This is especially true for those patients with HER2 HercepTest® scores of 2+, who are not eligible for HER2-targeted therapy," said Ulrik Nielsen, PhD, Co-Founder and Chief Scientific Officer of Merrimack. "We are excited to further examine MM-111's potential to delay resistance and restore sensitivity to standard of care treatments in this aggressive disease."

1 of 2

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
DOW 17,067.56 -30.89 -0.18%
S&P 500 2,002.28 -1.09 -0.05%
NASDAQ 4,598.1880 +17.9170 0.39%

Brokerage Partners

Rates from Bankrate.com

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs